

Day 3: Sept 16, 2021

## A Place for TB in the Pandemic Preparedness Agenda

- Tharman Shanmugaratnam, Senior Minister, Singapore and co-chair, G20 High Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response

## Achieving Synergy in Global Health Security Preparedness against Respiratory Pathogens: Recognition of TB as a Leading Killer

- John Bell, University of Oxford
- Bruce Gellin, The Rockefeller Foundation
- Rebecca Katz, Georgetown University, Center for Global Health Science and Security
- Michael Callahan, Massachusetts General Hospital; Department of Defense

## Making the Case for Financing TB Elimination

- Margaret Hamburg, moderator, Nuclear Threats Initiative

## The Cost of Failing to Achieve the End TB Targets: A Full Economic Analysis

- Michael Reid, University of California, San Francisco

## Why TB is One of the Best Investments on the SDG Agenda

- Bjorn Lomborg, Copenhagen Consensus Center

## Innovations for Tackling Tuberculosis in the Time of COVID-19: Smart Investments in Ending TB

- Mark Dybul, Georgetown University; Enochian BioSciences

## Implications for TB from the High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response

- Amanda Glassman, Center for Global Development

## Planning Committee

- Gail Cassell, Harvard Medical School (*co-chair*)
- Kenneth Castro, Emory University (*co-chair*)
- Emily Abraham, Johnson & Johnson
- Andrew Clements, U.S. Agency for International Development
- Lucica Ditiu, Stop TB Partnership
- Marcos Espinal, Pan American Health Organization
- Hamidah Hussain, Innovative Research & Development
- Tereza Kasaeva, World Health Organization
- Kent Kester, Sanofi Pasteur
- Monique Mansoura, MITRE
- Peter Sands, The Global Fund to Fight AIDS, Tuberculosis and Malaria
- Charles Wells, Bill & Melinda Gates Medical Research Institute

## Sponsor

U.S. Agency for International  
Development (USAID)